valsartan has been researched along with Hypertrophy, Right Ventricular in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choudhary, G; Clements, RT; Fernandez-Nicolas, A; Kue, NR; Mallem, K; Mancini, TJ; McCullough, DJ; Morrison, AR; Vang, A | 1 |
| Chen, W; Dong, J; Gao, D; Guo, H; Lu, Y; Pan, X; Sun, Y; Xu, D; Xu, Y | 1 |
| Andersen, A; Andersen, S; Axelsen, JB; Bogaard, HJ; de Man, FS; Hyldebrandt, JA; Nielsen-Kudsk, JE; Nyengaard, JR; Ringgaard, S | 1 |
3 other study(ies) available for valsartan and Hypertrophy, Right Ventricular
| Article | Year |
|---|---|
Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterial Pressure; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Female; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Neprilysin; Protease Inhibitors; Pulmonary Artery; Rats, Sprague-Dawley; Tetrazoles; Valsartan; Vascular Remodeling; Ventricular Dysfunction, Right; Ventricular Function, Right; Ventricular Remodeling | 2019 |
Valsartan attenuates pulmonary hypertension via suppression of mitogen activated protein kinase signaling and matrix metalloproteinase expression in rodents.
Topics: Animals; Blood Pressure; Cell Proliferation; Extracellular Matrix; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; MAP Kinase Signaling System; Matrix Metalloproteinases; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Monocrotaline; Phosphorylation; Rats, Sprague-Dawley; Systole; Transforming Growth Factor beta1; Valsartan; Vascular Remodeling | 2017 |
Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure.
Topics: Aminobutyrates; Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Pulmonary Circulation; Rats; Tetrazoles; Valsartan; Vascular Remodeling; Ventricular Dysfunction, Right | 2019 |